drugset / Trial / NCT01038895

Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria

NCT01038895

Phase 4 Unknown 120 enrolled University of Pavia
RandomizedParallel-groupOpen-labelTreatment

Summary

The main objective of this study is to assess the extent and trend in time of antiproteinuric effect as well as that antihypertensive effect of aliskiren 300 mg / d versus ramipril 10 mg daily in hypertensive patients with type 2 diabetes and microalbuminuria. The investigators will also evaluate: 1. Average of 24 hours, as determined by ABPM, systolic and diastolic blood pressure checks at various visits 2. Average daytime, as determined by ABPM, systolic and diastolic blood pressure checks at various visits 3. Average night, as determined by ABPM, systolic and diastolic blood pressure checks at various visits

Timeline

Start
2009-11
Primary completion
2010-03
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg
Comparator Ramipril Small molecule 10 mg